Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of erlotinib hydrochloride in
preventing cancer in patients with precancerous lesions of the lung. Erlotinib hydrochloride
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.